Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial have?
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial has 16 citations in the OpenAlex counts ScholarIQ stores.
When was Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial published?
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial has 2026 year in the ScholarIQ index.
What is the open-access status of Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial?
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial has hybrid oa status in the ScholarIQ index.
What is the DOI of Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial?
The DOI for Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial is on the source record.
What is the PMID of Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial?
The PMID for Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial is on the source record.
What is the OpenAlex record for Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial?
The OpenAlex for Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial is on the source record.